secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001213900-25-010748
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LYMPHIR assigned permanent J-code J9161 by CMS, effective April 1, 2025
-----------------------------------------------------------------------

- LYMPHIR (denileukin diftitox-cxdl) received permanent HCPCS J-code J9161 for IV use, 1 microgram.
- J-code effective April 1, 2025, for claims submission by healthcare providers.
- Code facilitates billing and reimbursement for commercial and government insurance (VA, DoD, Medicare).
- Chairman Leonard Mazur states milestone supports patient access and coding clarity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/0001213900-25-010748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/ea0230157-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-010748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer